PK/PD Study With G-Pump (Glucagon Infusion) in T1DM Patients

Completed · Phase 2

Conditions studied: Hypoglycemia

In brief

The purpose of the study is to assess the safety, speed of absorption, and onset of action of G-Pump™ (glucagon infusion) at three subcutaneous doses as compared to Novo GlucaGen®, all delivered via an OmniPod® infusion pump to patients with type 1 diabetes.

Key facts

Study ID

NCT02081001

Run by

Xeris Pharmaceuticals

People needed

19

Starts

2014-03-01

Expected to finish

2014-09-01

Last updated by the study team

2018-04-06

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males or females diagnosed with type 1 diabetes mellitus for at least 24 months
• Current usage of subcutaneous insulin pump treatment
• Age 18-65 years
• C-peptide level < 0.5 ng/ml
• Willingness to follow all study procedures, including attending all clinic visits
• Subject has provided informed consent and has signed and dated an informed consent form before any trial-related activities

You may not qualify if…

• Pregnant and/ or Lactating: For women of childbearing potential: there is a requirement for a negative urine pregnancy test and for agreement to use contraception during the study and for at least 1 month after participating in the study.
• HbA1c >10.0%
• Renal insufficiency (serum creatinine of 1.2 mg/dL or greater)
• Serum ALT or AST equal to or greater than 3 times the upper limit of normal; hepatic synthetic insufficiency as defined as a serum albumin of less than 3.0 g/dL; or serum bilirubin of over 2.0.
• Hematocrit of less than or equal to 34%
• Congestive heart failure, NYHA class II, III or IV
• History of coronary artery disease
• Active foot ulceration
• History of a cerebrovascular accident
• Active alcohol abuse or substance abuse
• Active malignancy, except basal cell or squamous cell skin cancers
• Major surgical operation within 30 days prior to screening
• Seizure disorder
• Current administration of oral or parenteral corticosteroids
• Use of an investigational drug within 30 days prior to screening
• Bleeding disorder, treatment with warfarin, or platelet count below 50,000
• Proliferative or severe non-proliferative retinopathy
• Gastroparesis
• Personal or family history of pheochromocytoma or disorder with increased risk of pheochromocytoma (MEN 2, neurofibromatosis, or Von Hippel-Lindau disease)
• Insulinoma
• Allergies to glucagon or glucagon-like products, or any history of significant hypersensitivity to glucagon or any related products.
• Glycogen storage disease
• Any concurrent illness, other than diabetes, that is not controlled by a stable therapeutic regimen
• Whole blood donation of 1 pint (500 mL) within 8 weeks prior to Screening.
• Any reason the principal investigator deems exclusionary

Where it is running

• Oregon Health & Science University — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.